Association of plasma VEGF-A, soluble VEGFR-1 and VEGFR-2 levels and clinical response and survival in advanced colorectal cancer patients receiving bevacizumab with modified FOLFOX6.

For individualized bevacizumab-based therapy, non-invasive biomarkers are necessary. This study assessed the predictive value of plasma vascular endothelial growth factor (VEGF)-A, soluble VEGF receptor (sVEGFR)-1 and sVEGFR-2 levels as biomarkers for clinical response and survival in advanced colorectal cancer (CRC) patients treated with bevacizumab and modified FOLFOX6 (mFOLFOX6). Forty-six unresectable advanced CRC patients and 20 healthy controls were included in this study. CRC patients were treated with bevacizumab and mFOLFOX6. Pretreatment plasma VEGF-A, sVEGFR-1 and sVEGFR-2 levels were measured using the multiplex immunoassay. Plasma VEGF-A, sVEGFR-1 and sVEGFR-2 levels were significantly higher in CRC patients than in the healthy subjects. The plasma sVEGFR-1 levels in the responder patients [complete response (CR)/partial response (PR)] and stable disease (SD) patients were significantly lower than those in the progressive disease (PD) patients (CR/PR vs. PD, p=0.025; SD vs. PD, p=0.032), while the plasma VEGF-A and sVEGFR-2 levels did not show any significant differences between the two groups of patients. Patients with higher sVEGFR-1 levels showed a significantly poorer progression-free survival (PFS) and overall survival (OS) than those with lower VEGFR-1 levels. In contrast, VEGF-A and sVEGFR-2 did not show any significant relationship between PFS and OS according to the status of each level. In the multivariate Cox proportional hazard regression analysis, sVEGFR-1 levels showed a significant relationship between PFS and OS. These results suggest that plasma sVEGFR-1 levels have a predictive value for clinical response and survival in advanced CRC patients treated with bevacizumab and mFOLFOX6. Larger scale studies are needed to further validate our results.

[1]  J. Iwasaki,et al.  Anti-angiogenic therapy against gastrointestinal tract cancers. , 2009, Japanese journal of clinical oncology.

[2]  Jeffrey W. Clark,et al.  Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Jerry Younger,et al.  VEGF as a Marker for Outcome Among Advanced Breast Cancer Patients Receiving anti-VEGF Therapy with Bevacizumab and Vinorelbine Chemotherapy , 2008, Clinical Cancer Research.

[4]  Dongsheng Tu,et al.  K-ras mutations and benefit from cetuximab in advanced colorectal cancer. , 2008, The New England journal of medicine.

[5]  I. Burney,et al.  Measurement of circulating levels of VEGF-A, -C, and -D and their receptors, VEGFR-1 and -2 in gastric adenocarcinoma. , 2008, World journal of gastroenterology.

[6]  U. Ozbek,et al.  Prognostic and predictive value of vascular endothelial growth factor and its soluble receptors, VEGFR-1 and VEGFR-2 levels in the sera of small cell lung cancer patients , 2008, Medical oncology.

[7]  S. Steinberg,et al.  Circulating biomarkers of bevacizumab activity in patients with breast cancer , 2008, Cancer biology & therapy.

[8]  A. Shamseddine,et al.  Vascular endothelial growth factor family of ligands and receptors: review. , 2007, Blood cells, molecules & diseases.

[9]  H. Matsumoto,et al.  Overexpression of soluble vascular endothelial growth factor receptor 1 in colorectal cancer: Association with progression and prognosis , 2007, Cancer science.

[10]  F. Tas,et al.  Circulating serum levels of angiogenic factors and vascular endothelial growth factor receptors 1 and 2 in melanoma patients , 2006, Melanoma research.

[11]  L. Claesson‐Welsh,et al.  VEGF receptor signalling ? in control of vascular function , 2006, Nature Reviews Molecular Cell Biology.

[12]  Ricky T. Tong,et al.  Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  H. Hurwitz,et al.  Benefit from bevacizumab (BV) is independent of pretreatment plasma vascular endothelial growth factor-A (pl-VEGF) in patients (pts) with metastatic colorectal cancer (mCRC) , 2005 .

[14]  L. Ellis,et al.  Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  E. Lower,et al.  Use of complementary/alternative therapies during chemotherapy for breast cancer , 2004 .

[16]  F. Ciardiello,et al.  Determination of Molecular Marker Expression Can Predict Clinical Outcome in Colon Carcinomas , 2004, Clinical Cancer Research.

[17]  E. Estey,et al.  Soluble vascular endothelial growth factor receptor 1, and not receptor 2, is an independent prognostic factor in acute myeloid leukemia and myelodysplastic syndromes , 2004, Cancer.

[18]  T. Robak,et al.  Circulating VEGF and its soluble receptors sVEGFR-1 and sVEGFR-2 in patients with acute leukemia. , 2003, European cytokine network.

[19]  N. Ferrara,et al.  The biology of VEGF and its receptors , 2003, Nature Medicine.

[20]  G. Yancopoulos,et al.  VEGF-Trap: A VEGF blocker with potent antitumor effects , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[21]  Masakazu,et al.  Significance of vascular endothelial growth factor (VEGF)/soluble VEGF receptor‐1 relationship in breast cancer , 2002, International journal of cancer.

[22]  H. Nielsen,et al.  Prognostic impact of matched preoperative plasma and serum VEGF in patients with primary colorectal carcinoma , 2002, British Journal of Cancer.

[23]  D. Hinton,et al.  Vascular endothelial growth factor (VEGF) is an autocrine growth factor for VEGF receptor-positive human tumors. , 2001, Blood.

[24]  A. Harris,et al.  Soluble Tie2 and Flt1 extracellular domains in serum of patients with renal cancer and response to antiangiogenic therapy. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[25]  S. Fan,et al.  Clinical implications of circulating angiogenic factors in cancer patients. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  R. Broll,et al.  Vascular endothelial growth factor (VEGF)--a valuable serum tumour marker in patients with colorectal cancer? , 2001, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[27]  M. Shibuya.  Structure and function of VEGF/VEGF-receptor system involved in angiogenesis. , 2001, Cell structure and function.

[28]  N. Fusenig,et al.  Expression and functional significance of vascular endothelial growth factor receptors in human tumor cells. , 1999, Laboratory investigation; a journal of technical methods and pathology.

[29]  Napoleone Ferrara,et al.  Clinical applications of angiogenic growth factors and their inhibitors , 1999, Nature Medicine.

[30]  R. Kendall,et al.  Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. , 1996, Biochemical and biophysical research communications.

[31]  L. Ellis,et al.  Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. , 1995, Cancer research.

[32]  R. Kendall,et al.  Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[33]  Ma Dong,et al.  Bevacizumab plus Irinotecan,Fluorouracil,and Leucovorin for Metastatic Colorectal Cancer , 2006 .

[34]  A. Harris,et al.  A critical review of vascular endothelial growth factor (VEGF) analysis in peripheral blood: Is the current literature meaningful? , 2004, Clinical & Experimental Metastasis.